Loading…
AEON Biopharma, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AEON.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $1.10 | $38.88 | |
| P/E | — | — | 0.5x |
| EPS | -$3.95 | $72.93 |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HINDVyome Holdings, Inc | $2.21 | — | 2.6x | — | -999.17% | $15.48M |
| NRSNNeuroSense Therapeutics Ltd. | $0.42 | — | — | — | -2174.98% | $15.88M |
| ADVBAdvanced Biomed Inc. | $9.70 | 2.4x | 1.5x | — | 71.33% | $16.03M |
| NMTCNEUROONE MEDICAL TECHNOLOGIES Corp | $1.77 |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Company description provided by Yahoo Finance.
| — |
| 4.1x |
| — |
| -124.66% |
| $16.12M |
| LSTALisata Therapeutics Inc | $1.69 | — | 1.9x | — | -101.66% | $15.23M |
| SCNXScienture Holdings, Inc. | $0.39 | — | 0.3x | — | -53.47% | $16.18M |